Combined therapies for Duchenne muscular dystrophy to optimize treatment efficacy

Gonzalo Cordova, Elisa Negroni, Claudio Cabello-Verrugio, Vincent Mouly, Capucine Trollet

Research output: Contribution to journalShort surveypeer-review

24 Citations (Scopus)

Abstract

Duchene Muscular Dystrophy (DMD) is the most frequent muscular dystrophy and one of the most severe due to the absence of the dystrophin protein. Typical pathological features include muscle weakness, muscle wasting, degeneration, and inflammation. At advanced stages DMD muscles present exacerbated extracellular matrix and fat accumulation. Recent progress in therapeutic approaches has allowed new strategies to be investigated, including pharmacological, gene-based and cell-based therapies. Gene and cell-based therapies are still limited by poor targeting and low efficiency in fibrotic dystrophic muscle, therefore it is increasingly evident that future treatments will have to include "combined therapies" to reach maximal efficiency. The scope of this mini-review is to provide an overview of the current literature on such combined therapies for DMD. By "combined therapies" we mean those that include both a therapy to correct the genetic defect and an additional one to address one of the secondary pathological features of the disease. In this mini-review, we will not provide a comprehensive view of the literature on therapies for DMD, since many such reviews already exist, but we will focus on the characteristics, efficiency, and potential of such combined therapeutic strategies that have been described so far for DMD.

Original languageEnglish
Article number114
JournalFrontiers in Genetics
Volume9
Issue numberAPR
DOIs
Publication statusPublished - 10 Apr 2018

Keywords

  • Atrophy
  • Cell therapy
  • Duchenne muscular dystrophy
  • Dystrophin
  • Fibrosis
  • Gene therapy
  • Inflammation
  • Muscle

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'Combined therapies for Duchenne muscular dystrophy to optimize treatment efficacy'. Together they form a unique fingerprint.

Cite this